What is Advanced Cell Diagnostics?
Advanced Cell Diagnostics, Inc. is a leader in in situ hybridization technologies, renowned for its RNAscope and BaseScope assays. These cutting-edge tools are engineered for precise RNA detection and quantification across a diverse array of biological samples. The company's solutions are pivotal for research in oncology, neuroscience, and infectious diseases, enabling single-cell analysis and multi-omic profiling. Beyond its product offerings, Advanced Cell Diagnostics provides professional assay services, including biomarker and clinical assay development, supporting biopharma clients and researchers in accelerating drug development and diagnostics within the life sciences.
How much funding has Advanced Cell Diagnostics raised?
Advanced Cell Diagnostics has raised a total of $40.8M across 4 funding rounds:
Series A
$5.4M
Series B
$12M
Grant
$1.4M
Series C
$22M
Series A (2009): $5.4M with participation from Morningside Venture Investments
Series B (2012): $12M led by Morningside Ventures and New Leaf Venture
Grant (2014): $1.4M supported by National Cancer Institute
Series C (2015): $22M featuring New Leaf Venture Partners, Summit Partners, Morningside Ventures, and Kenson Ventures
Key Investors in Advanced Cell Diagnostics
New Leaf Venture Partners
New Leaf Venture Partners is a venture capital firm focused on funding innovative companies in the healthcare sector. They aim to support the healthcare revolution by investing in transformative technologies and solutions.
Summit Partners
Founded in 1984, Summit Partners is an equity investment company that invests in entrepreneurial companies. They are headquartered out of Boston, Massachusetts.
Kenson Ventures
Kenson Ventures provides seed money/funds and strategic advice to start-ups, partnerships, and established companies focusing in the biotechnology and life science areas. They also consider and participate in co-investment with other institutions.
What's next for Advanced Cell Diagnostics?
With a significant enterprise-level funding context and a recent strategic investment, Advanced Cell Diagnostics is well-positioned for its next phase of growth. The company's focus on innovative RNA detection technologies suggests a trajectory towards expanding its market reach in both academic research and clinical applications. Future developments may involve further integration of its assays into diagnostic workflows and the development of new multi-omic profiling tools, leveraging its established position to drive advancements in personalized medicine and therapeutic development.
See full Advanced Cell Diagnostics company page
